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Introduction: Epidermal growth factor receptor (EGFR) signaling
pathway plays a crucial role in the development and progression of
lung cancer. We searched for mutations of EGFR pathway genes in
non-small cell lung cancers (NSCLCs) and analyzed their relation-
ship with clinicopathologic features.
Methods: Mutations of EGFR, ERBB2, ERBB3, ERBB4, KRAS,
NRAS, BRAF, PTEN, PIK3CA, LKB1, and AKT1 genes were deter-
mined by direct sequencing in 173 surgically resected NSCLCs—56
squamous cell carcinomas (SCCs) and 117 adenocarcinomas (ACs).
Results: Of the 173 NSCLCs, a total of 65 mutations were detected
in 63 (36.4%) tumors—10 (17.9%) in SCCs and 53 (45.3%) in ACs.
Mutations in EGFR pathway genes were significantly more frequent
in women and ACs than in women and SCCs (p  0.02 and p 
0.001, respectively). The mutations occurred in a mutually exclusive
pattern. When the genes were divided into three subgroups accord-
ing to their roles in the signaling cascade, mutations in the EGFR/
ERBB2 and KRAS/BRAF genes were more frequent in ACs than in
SCCs (p  0.001 and p  0.01, respectively). In marked contrast,
mutations in the PIK3CA/PTEN were more frequent in SCCs than in
ACs (p  0.002). Furthermore, mutations in the PIK3CA/PTEN
genes were more frequent in smokers (p  0.04).
Discussion: Our study demonstrates that mutations in each part of
the EGFR pathway were associated with different clinicopathologic
features in patients with NSCLCs.
Key Words: Epidermal growth factor receptor (EGFR) pathway,
Mutation, Lung cancer.
(J Thorac Oncol. 2010;5: 1734–1740)
Epidermal growth factor receptor (EGFR) signaling path-way plays a crucial role in many carcinogenic processes
such as proliferation, angiogenesis, invasion, and metastasis, and
resistance to apoptosis.1,2 RAS/RAF/mitogen activated protein
kinase (MAPK), phosphatidylinosital 3-kinase (P13K)/AKT,
signal transducer and activator of transcription, v-src sarcoma
viral oncogene homolog (SRC)/focal adhesion kinase (FAK),
and phospholipase C pathways are known downstream signaling
cascades transducing EGFR activation signals, with RAS/RAF/
MAPK and PI3K/AKT being the two major pathways.3,4
Because deregulation of EGFR pathway genes has been
observed frequently in various types of tumors, including
non-small cell lung cancer (NSCLC), the development of
targeted agents for lung cancer therapy has focused mainly on
EGFR and its downstream signaling networks.4 Mutations in
the tyrosine kinase (TK) domain of the EGFR gene were
identified in a subgroup of lung cancer having a good re-
sponse to EGFR TK inhibitors.5,6 In addition, alterations of
several genes in the EGFR pathway have been reported to be
associated with a clinical response to EGFR TK inhibi-
tors.7–10 A comprehensive understanding of mutations in
EGFR signaling pathway genes may, therefore, lead to opti-
mized therapeutic approaches to lung cancer.11
It has been reported that the prevalence of mutations in
several EGFR pathway genes, such as EGFR, KRAS, and
LKB1 differed among various ethnic groups,12,13 which may
reflect the difference in genetic and epidemiologic character-
istics of lung cancer among them. Furthermore, there have
been a limited number of studies that comprehensively in-
vestigated mutations in EGFR pathway genes, although indi-
vidual genes in this pathway have been widely investigated.
In this study, we searched for mutations in EGFR signaling
pathway genes in Korean patients with NSCLCs, combining
our previously reported data on PTEN and LKB1 mutations in
lung cancers,14,15 correlating the results with clinicopatho-
logic features.
PATIENTS AND METHODS
Patients and Tissue Samples
After obtaining approval from the institutional review
board and the patients’ written informed consent, primary
lung tumors and matching nonmalignant lung tissues and
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peripheral blood lymphocytes were obtained from 173 pa-
tients with NSCLC who underwent resection with curative
intend at Kyungpook National University Hospital (Daegu,
Korea) from January 2003 to July 2007. All patients included
in this study were ethnic Koreans. Patients who underwent
chemotherapy or radiotherapy before surgery were excluded
to avoid the effects on DNA. The clinicopathologic charac-
teristics of the patients are summarized in Table 1. Histologic
type of the tumors was determined according to World Heath
Organization criteria16: 56 tumors were squamous cell carci-
nomas (SCCs) (32.4%) and 117 were adenocarcinomas
(ACs) (67.6%). There were 113 men (65.3%) and 60 women
(34.7%), with age at diagnosis ranging from 40 to 82 years in
men (median age, 64 years) and 35 to 79 years in women
(median age, 62 years). Patients consisted of 56 never smok-
ers (32.4%) and 117 smokers (67.6%). Of the 117 AC cases,
53 were never smokers (45.3%). Pathologic staging of lung
cancers was determined according to the revised lung cancer
staging system17: 90 (52.0%) had stage I disease, 54 (31.2%)
stage II, and 29 (16.8%) stage III. All the tumor and macro-
scopically normal lung tissue samples were obtained at the
time of surgery, rapidly frozen in liquid nitrogen and stored at
80°C. The slides of the tissue sections stained with hema-
toxylin and eosin were analyzed by a pathologist. Only
specimens with greater than 80% tumor component were sent
forward for DNA extraction and mutation analysis. All the
macroscopically normal samples were confirmed as normal
by hematoxylin and eosin staining.
Mutational Analysis of the EGFR Pathway
Genes
In this study, the mutations in 11 EGFR signaling
pathway genes—EGFR, ERBB2, ERBB3, ERBB4, KRAS,
NRAS, BRAF, PTEN, PIK3CA, LKB1, and AKT1—were ex-
amined. We previously examined the same cohort for TP53
(exons 2–11), PTEN (exons 1–9), and LKB1 (exons 1–9)
mutations.14,15,18 Mutational analysis of EGFR (exons 18–
21), ERBB2 (exons 19 and 20), ERBB3 (exons 2, 3, 7, and 8),
ERBB4 (exon 23), KRAS (exon 2), NRAS (exon 2), BRAF
(exons 11 and 15), PIK3CA (exons 9 and 20), and AKT1
(exon 3) was performed by polymerase chain reaction (PCR)-
based direct sequencing. The primers and conditions for PCR
reactions are shown in Supplementary Table 1 (available at:
http://links.lww.com/JTO/A34). The PCR products were pu-
rified using a GENECLEAN Turbo kit (Q-Biogene, Carlsbad,
CA). All sequence variants were confirmed by sequencing the
products of independent PCR amplifications in both direc-
tions. Sequencing was done using an ABI Prism 3100 Ge-
netic Analyzer (PE Biosystems, Foster City, CA). Nomen-
clature for the description of all sequence variations were
according to the guidelines for mutation nomenclature by
human genome variation society.19
Statistical Analysis
The association between mutations in EGFR signaling
pathway genes and clinicopathological characteristics was
analyzed using either a 2 test or Fisher’s exact test. All
statistical tests were two sided, and a p value less than 0.05
was considered statistically significant.
RESULTS
Of the 173 NSCLCs, a total of 65 mutations of EGFR
pathway genes were detected in 63 tumors (36.4%). All the
mutations found in the tumors were absent in DNA from the
matched nonmalignant lung tissues and blood lymphocytes,
indicating that these were somatic mutations. The frequency
of mutations in each gene were 20.8% (36/173) for EGFR,
1.2% (2/173) for ERBB2, 6.4% (11/173) for KRAS, 1.2%
(2/173) for BRAF, 2.9% (5/173) for PIK3CA, 4.6% (8/173)
for PTEN, and 0.6% (1/173) for LKB1. There were no
mutations observed in ERBB3, ERBB4, NRAS, or AKT1.
There were two ACs with double mutations: one had an
EGFR exon19 deletion mutation and a PTEN mutation
(p.Tyr155His) and one had a KRAS mutation (p.Gly12Cys)
and a BRAF mutation (p.Phe595Leu). Table 2 details muta-
tions in each mutation-positive case.
EGFR mutations were more frequent in women than in
men (35.0% versus 13.3%, p  0.001) and in never smokers
than in ever smokers (37.5% versus 12.8%, p  0.001). In
addition, the mutations were only detected in ACs (30.8%),
and not in SCCs (p  0.001) (Table 3). Of the 36 EGFR
mutations, 26 (72.2%) were missense point mutations
(p.Leu858Arg) in exon 21, seven (19.4%) were in-frame
deletions in exon 19, and three (8.3%) were in-frame dupli-
cating insertions in exon 20. There were two in-frame inser-
tions in ERBB2 in two ACs (1.7% in ACs). KRAS mutations
were only detected in ACs (9.4%) and not in SCCs (p 
0.02). All the 11 KRAS mutations were missense point mu-
tations at codon 12. There were two ACs carrying BRAF
mutations in kinase domain: one (p.Gly469Val) in the gly-
cine-rich GXGXXG motif within the phosphate binding loop of
exon 11 and one (p.Phe595Leu) in the activation segment of
exon 15. PIK3CA mutations were significantly more frequent in
SCCs than in ACs (7.1% [4/56] versus 0.9% [1/117], p 0.04).
Of the 5 PIK3CA gene mutations, three were missense point
mutations in the helical domain (p.Glu542Lys, p.Glu545Ala,
TABLE 1. Patient Characteristics
Variables Total SCC AC p
Sample size 173 56 117
Age (yr), mean 
SD
62.7  8.8 64.5  7.9 61.9  9.1 0.073a
Sex, n (%)
Male 113 (65.3) 52 (92.9) 61 (52.1) 0.001b
Female 60 (34.7) 4 (7.1) 56 (47.9)
Smoking status,
n (%)
Ever 117 (67.6) 53 (94.6) 64 (54.7) 0.001b
Never 56 (32.4) 3 (5.4) 53 (45.3)
Pathologic stages,
n (%)
Stage I 90 (52.0) 30 (53.6) 60 (51.3) 0.568b
Stage II 54 (31.2) 19 (33.9) 35 (29.9)
Stage III 29 (16.8) 7 (12.5) 22 (18.8)
a t test, SCC vs. AC.
b 2 test, SCC vs. AC.
AC, adenocarcinoma; SCC, squamous cell carcinoma; SD, standard deviation.
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TABLE 2. Genetic Alterations in the EGFR Pathway Genes in Non-small Cell Lung Cancers
No. Histology
Sex/Age
(yr) Smoking Gene Exon Nucleotide Alteration Amino Acid Alteration
1 AC F/49 Never EGFR 19 c.2240_2254delTAAGAGAAGCAACAT p.Leu747_Thr751del
2 AC F/60 Never EGFR 19 c.2237_2255delAATTAAGAGAAGCAACATCinsT p.Glu746_Ser752delinsVal
3 AC F/67 Never EGFR 19 c.2235_2249delGGAATTAAGAGAAGC; 2260AG p.Glu746_Ala750del;Lys754Glu
4 AC M/66 Ever EGFR 19 c.2235_2249delGGAATTAAGAGAAGC p.Glu746_Ala750del
5 AC M/41 Ever EGFR 19 c.2239_2247delTTAAGAGAA p.Leu747_Glu749del
6 AC M/65 Ever EGFR 19 c.2235_2249delGGAATTAAGAGAAGC p.Glu746_Ala750del
7 AC M/75 Ever EGFR 19 c.2239_2251delTTAAGAGAAGCAAinsC p.Leu747_Thr751delinsPro
PTEN 5 c.463TC p.Tyr155His
8 AC F/67 Never EGFR 20 c.2296_2297insTGGCCAGCG p.Ala767_Val769dup
9 AC F/51 Never EGFR 20 c.2311_2312insGCGTGGACA p.Ser768_Asp770dup
10 AC M/46 Ever EGFR 20 c.2308_2309insACAACCCCC p.Asn771_His773dup
11 AC F/54 Never EGFR 21 c.2573TG p.Leu858Arg
12 AC F/41 Never EGFR 21 c.2573TG p.Leu858Arg
13 AC F/65 Never EGFR 21 c.2573TG p.Leu858Arg
14 AC F/72 Never EGFR 21 c.2573TG p.Leu858Arg
15 AC F/65 Never EGFR 21 c.2573TG p.Leu858Arg
16 AC F/69 Never EGFR 21 c.2573TG p.Leu858Arg
17 AC F/68 Never EGFR 21 c.2573TG p.Leu858Arg
18 AC F/69 Never EGFR 21 c.2573TG p.Leu858Arg
19 AC F/60 Never EGFR 21 c.2573TG p.Leu858Arg
20 AC F/58 Never EGFR 21 c.2573TG p.Leu858Arg
21 AC F/62 Never EGFR 21 c.2573TG p.Leu858Arg
22 AC F/67 Never EGFR 21 c.2573TG p.Leu858Arg
23 AC F/60 Never EGFR 21 c.2573TG p.Leu858Arg
24 AC F/58 Never EGFR 21 c.2573TG p.Leu858Arg
25 AC F/59 Never EGFR 21 c.2573TG p.Leu858Arg
26 AC F/58 Never EGFR 21 c.2573TG p.Leu858Arg
27 AC M/62 Ever EGFR 21 c.2573TG p.Leu858Arg
28 AC M/66 Ever EGFR 21 c.2573TG p.Leu858Arg
29 AC M/54 Ever EGFR 21 c.2573TG p.Leu858Arg
30 AC M/47 Ever EGFR 21 c.2573TG p.Leu858Arg
31 AC M/40 Ever EGFR 21 c.2573TG p.Leu858Arg
32 AC M/67 Ever EGFR 21 c.2573TG p.Leu858Arg
33 AC M/64 Ever EGFR 21 c.2573TG p.Leu858Arg
34 AC M/55 Ever EGFR 21 c.2573TG p.Leu858Arg
35 AC M/72 Ever EGFR 21 c.2573TG p.Leu858Arg
36 AC M/66 Ever EGFR 21 c.2573TG p.Leu858Arg
37 AC F/57 Never ERBB2 20 c.2326_2327insTCT p.Gly776delinsValCys
38 AC M/46 Ever ERBB2 20 c.2322_2323insGCATACGTGATG p.Ala775_Gly776insAlaTyrValMet
39 AC F/49 Never KRAS 1 c.35GA p.Gly12Asp
40 AC F/69 Never KRAS 1 c.35GA p.Gly12Asp
41 AC F/58 Never KRAS 1 c.34GT p.Gly12Cys
BRAF 15 c.1785TG p.Phe595Leu
42 AC M/65 Ever KRAS 1 c.35GT p.Gly12Val
43 AC M/58 Ever KRAS 1 c.35GT p.Gly12Val
44 AC M/55 Ever KRAS 1 c.34GC p.Gly12Arg
45 AC M/62 Ever KRAS 1 c.35GA p.Gly12 Asp
46 AC M/50 Ever KRAS 1 c.35GA p.Gly12 Asp
47 AC M/67 Ever KRAS 1 c.35GA p.Gly12Asp
48 AC M/52 Ever KRAS 1 c.34GT p.Gly12Cys
49 AC M/63 Ever KRAS 1 c.34GT p.Gly12Cys
50 AC M/59 Ever BRAF 11 c.1406GT p.Gly469Val
51 AC F/76 Ever PIK3CA 9 c.1633GA p.Glu545Lys
(Continued)
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and p.Glu545Lys) and two in the kinase domain (p.Met1043Val,
and p.His1047Arg) of p110 catalytic subunit of PI3K. All the
PIK3CA mutations were activating mutations occurring at hot
spots. The PTEN mutations were significantly more frequent
in SCCs than in ACs (10.7% [6/56] versus 1.7% [2/117], p
0.01). All the eight PTEN mutations occurred in ever smokers
(6.8% [8/117], p  0.06 versus never smokers). There were
six mutations in the phosphatase domain (p.Lys125Asn,
p.Arg130X, p.Arg130Gly, p.Tyr155His, p.Gly165X, and
p.Tyr180X) and two mutations in the C2 domain (p.Ser229X
and c.944_945insCT, a frameshift mutation). A single LKB1
mutation (c.842delC, a frameshift mutation) was found in a
male ever smoker with AC (0.6% [1/173] in NSCLCs and
0.9% [1/117] in ACs). The mutations in EGFR pathway
genes showed a mutually exclusive pattern.
Collectively, mutations in EGFR pathway genes were
significantly more frequent in women than in men (48.3%
versus 30.1%, p  0.02) and in ACs compared with SCCs
(45.3% versus 17.9%, p  0.001) (Table 4). The mutations
tended to be more frequent in never smokers than in ever
smokers (46.4% versus 31.6%, p  0.06); however, the




(yr) Smoking Gene Exon Nucleotide Alteration Amino Acid Alteration
52 SCC M/72 Ever PIK3CA 9 c.1624GA p.Glu542Lys
53 SCC M/63 Ever PIK3CA 9 c.1634AC p.Glu545Ala
54 SCC F/60 Ever PIK3CA 20 c.3127AG p.Met1043Val
55 SCC M/68 Never PIK3CA 20 c.3140AG p.His1047Arg
56 AC M/67 Ever PTEN 5 c.375AT p.Lys125Asn
57 SCC F/66 Ever PTEN 5 c.388CT p.Arg130X
58 SCC F/62 Ever PTEN 5 c.388CG p.Arg130Gly
59 SCC M/59 Ever PTEN 6 c.493GT p.Gly165X
60 SCC M/66 Ever PTEN 6 c.540CG p.Tyr180X
61 SCC M/62 Ever PTEN 7 c.686CG p.Ser229X
62 SCC M/54 Ever PTEN 8 c.944_945insCT p.Leu316PhefsX2
63 AC M/77 Ever LKB1 6 c.842delC p.Pro281ArgfsX6
AC, adenocarcinoma; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor.
TABLE 3. Correlation of Mutations in EGFR Pathway Genes with Clinicopathological Features
Variables
Mutation Frequency, No. (%)
EGFR ERBB2 KRAS BRAF PIK3CA PTEN LKB1
Overall (n  173) 36 (20.8) 2 (1.2) 11 (6.4) 2 (1.2) 5 (2.9) 8 (4.6) 1 (0.6)
Age (yr)
64 (n  93) 20 (21.5) 2 (2.2) 8 (8.6) 2 (2.2) 2 (2.2) 4 (4.3) 0 (0.0)
64 (n  80) 16 (20.0) 0 (0.0) 3 (3.8) 0 (0.0) 3 (3.8) 4 (5.0) 1 (1.3)
p 0.81 0.50 0.19 0.50 0.66 1.00 0.46
Gender
Male (n  113) 15 (13.3) 1 (0.9) 8 (7.1) 1 (0.9) 3 (2.7) 6 (5.3) 1 (0.9)
Female (n  60) 21 (35.0) 1 (1.7) 3 (5.0) 1 (1.7) 2 (3.3) 2 (3.3) 0 (0.0)
p 0.001 1.00 0.75 1.00 1.00 0.72 1.00
Smoking status
Never (n  56) 21 (37.5) 1 (1.8) 3 (5.4) 1 (1.8) 1 (1.8) 0 (0.0) 0 (0.0)
Ever (n  117) 15 (12.8) 1 (0.9) 8 (6.8) 1 (0.9) 4 (3.4) 8 (6.8) 1 (0.9)
p 0.001 0.54 1.00 0.54 1.00 0.06 1.00
Histologic type
SCC (n  56) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (7.1) 6 (10.7) 0 (0.0)
AC (n  117) 36 (30.8) 2 (1.7) 11 (9.4) 2 (1.7) 1 (0.9) 2 (1.7) 1 (0.9)
p 0.001 1.00 0.02 1.00 0.04 0.01 1.00
Pathologic stage
Stage I (n  90) 18 (20.0) 0 (0.0) 8 (8.9) 2 (2.2) 3 (3.3) 2 (2.2) 1 (1.1)
Stages II–III (n  83) 18 (21.7) 2 (2.4) 3 (3.6) 0 (0.0) 2 (2.4) 6 (7.2) 0 (0.0)
p 0.79 0.23 0.16 0.50 1.00 0.16 1.00
AC, adenocarcinoma; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor.
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TP53 mutation status of the tumors. For further analysis,
based on their roles in the signaling cascade, the genes in the
EGFR pathway were separated into subgroups—receptor TK
genes (EGFR/ERBB2) and genes in each downstream path-
way (KRAS/BRAF and PIK3CA/PTEN/LKB1). Mutations in
EGFR/ERBB2 genes occurred in 22% of all tumors (38/173),
all of which were ACs (32.5% in ACs, p  0.001 versus
SCCs), and were significantly more frequent in women than
in men (36.7% versus 14.2%, p  0.001) and in never
smokers than in ever smokers (39.3% versus 13.7%, p 
0.001). In regard to the TP53 mutation status, the EGFR/
ERBB2 mutations were more frequent in tumors without
TP53 mutations than in those with (26.9% versus 13.8%, p
0.05). Mutations in KRAS/BRAF genes were found in 12 of
173 tumors studied (6.9%), and all the mutations occurred in
ACs (10.3% in ACs, p  0.01 versus SCCs). In PIK3CA/
PTEN/LKB1 genes, mutations were found in 8.1% (14/173)
of NSCLCs and were more frequent in ever smokers than in
never smokers (11.1% versus 1.8%, p  0.04) and in SCCs
compared with ACs (17.9% versus 3.4%, p  0.002).
DISCUSSION
We describe in this study for the first time the collective
mutations in EGFR signaling pathway genes of Korean pa-
tients with NSCLCs. Mutations in EGFR pathway genes were
found in 17.9% of SCCs and 45.3% of ACs. When the genes
in the EGFR pathway were separated into subgroups based on
their roles in the signaling cascade, mutations in EGFR/
ERBB2 genes and KRAS/BRAF genes were found only in
ACs, whereas mutations in PIK3CA/PTEN genes occurred
more frequently in SCCs than in ACs. Consistent with pre-
vious studies, the mutations in EGFR pathway genes oc-
curred in a mutually exclusive pattern.
The most interesting finding of this study was that
mutations in the EGFR signaling pathway were relatively
common in SCCs. When the genes were divided into three
subgroups based on their roles in the signaling cascade,
mutations in PIK3CA/PTEN were more frequent in SCCs and
ever smokers than in ACs and never smokers. In SCCs, the
frequency of PIK3CA/PTEN mutations was 17.9%, which
was higher than 10.3% of KRAS/BRAF mutations in ACs.
Furthermore, 12 of the 13 mutations in PIK3CA/PTEN genes
occurred in smokers. These findings suggest that mutations of
PIK3CA/PTEN genes play an important role in the pathogen-
esis of smoking related lung cancers. Although mutations in
the PI3K/AKT pathway have been reported to be relatively
rare in lung cancers,20–22 mounting evidence indicates that
some alterations in this pathway may target SCCs. Studies
have reported that PIK3CA amplifications were more fre-
quent in SCCs than in ACs.23,24 Consistent with our results,
Kawano et al.21 reported that PIK3CA mutations were signif-
icantly more frequent in SCCs than in ACs in Japanese
patients with lung cancer. In addition, we previously reported
that PTEN mutations were significantly more frequent in
SCCs than in ACs and were only found in smokers.14 Based
on these observations, mutations in these genes may play an
important role in the pathogenesis of SCCs.
TABLE 4. Correlation of Mutations in Each Part of the EGFR Pathway—Receptor Tyrosine Kinases and Downstream Signaling
Pathways—and Clinicopathologic Features
Variables
Mutation Positive Cases, No. (%)
Overall
Receptor Tyrosine
Kinases Downstream Signaling Pathways
EGFR Pathway p EGFR/ERBB2 p RAS/BRAF p PIK3CA/PTEN/LKB1 p
Overall (n  173) 63 (36.4) 38 (22.0) 12 (6.9) 14 (8.1)
Age (yr)
64 (n  93) 37 (39.8) 22 (23.7) 9 (9.7) 6 (6.5)
64 (n  80) 26 (32.5) 0.32 16 (20.0) 0.56 3 (3.8) 0.13 8 (10.0) 0.39
Gender
Male (n  113) 34 (30.1) 16 (14.2) 9 (8.0) 10 (8.8)
Female (n  60) 29 (48.3) 0.02 22 (36.7) 0.001 3 (5.0) 0.55 4 (6.7) 0.77
Smoking status
Ever (n  117) 37 (31.6) 16 (13.7) 9 (7.7) 13 (11.1)
Never (n  56) 26 (46.4) 0.06 22 (39.3) 0.001 3 (5.4) 0.75 1 (1.8) 0.04
Histologic type
SCC (n  56) 10 (17.9) 0 (0.0) 0 (0.0) 10 (17.9)
AC (n  117) 53 (45.3) 0.001 38 (32.5) 0.001 12 (10.3) 0.01 4 (3.4) 0.002
Pathologic stage
Stage I (n  90) 32 (35.6) 18 (20.0) 9 (10.0) 6 (6.7)
Stages II–III (n  83) 31 (37.3) 0.81 20 (24.1) 0.52 3 (3.6) 0.10 8 (9.6) 0.47
TP53
Mutated (n  65) 21 (32.3) 9 (13.8) 5 (7.7) 7 (10.8)
Wild type (n  108) 42 (38.9) 0.38 29 (26.9) 0.05 7 (6.5) 0.77 7 (6.5) 0.32
AC, adenocarcinoma; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor.
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Mutations in EGFR pathway genes have been reported
to be mutually exclusive, suggesting that a single mutation in
the EGFR pathway leading to activation of the signaling
cascade may be enough for the pathogenesis of lung can-
cer.25,26 Consistent with previous studies,27,28 the mutations in
the EGFR pathway occurred in a mutually exclusive pattern.
However, there were two exceptions to this relationship in
our study. First, a PTEN mutation was found in the same AC
with an EGFR mutation. Genetic alterations in PIK3CA/
AKT/mTOR pathway, downstream from EGFR, may impact
the response to EGFR TKI in patients with lung cancer
carrying EGFR mutations because such alterations may un-
couple EGFR from downstream signaling. Sos et al.29 dem-
onstrated that PTEN loss induced a significant reduction in
apoptosis sensitivity in EGFR-mutant NSCLCs by activation
of Akt and EGFR and suggested PTEN loss as a mechanism
of erlotinib resistance. A concomitant inactivating PTEN
mutation, possibly as a mechanism of loss of heterozygosity,
in patients with an EGFR mutation may contribute to nonre-
sponsiveness to EGFR TKI. Second, a KRAS mutation was
found concurrently in an AC with a BRAF mutation. The
BRAF and KRAS mutations have been regarded to be mutu-
ally exclusive27,30; however, occasional RAS mutations were
reported to occur in the same cancers harboring uncommon
BRAF mutations.31,32 A single substitution in the activation
segment of kinase domain (p.Val599Glu), which has
greatly elevated kinase activity and is highly oncogenic,
accounts for 80% of BRAF mutations.31,32 In this study, a
missense mutation at codon 595 in activation segment was
present in the same tumor with a KRAS mutation. Although
its functional significance is unknown, this mutation might
not have enough oncogenic potential, thereby a concomi-
tant KRAS mutation could be required to generate a ma-
lignant transformation.
The prevalence of mutations in EGFR pathway genes in
our population was similar to previous reports in general.
EGFR mutations were found in 30.8% of ACs (39.6% in
never smokers and 23.4% in ever smokers), which is in
agreement with the reported prevalence of EGFR mutations
in AC (21–67%) in East Asian populations.33 In addition,
EGFR mutations were more frequent in women, never smok-
ers, and ACs than in men, ever smokers, and SCCs, as
reported in previous studies.27,34 KRAS mutations were found
in 6.4% of NSCLCs (9.4% of ACs) in our population. The
prevalence of KRAS mutations were in line with previous
reports in that the KRAS mutations were less common in East
Asian populations (4–10% of NSCLCs and 8–13% of ACs)
than in western populations (15–20% of NSCLCs and 20–
30% of ACs).35,36 Although PIK3CA mutations occur fre-
quently in many human cancers,21,37 studies have reported
that these mutations are relatively uncommon (4%) in lung
cancer. PIK3CA gene mutations were found in 2.9% of
NSCLCs (7.1% of SCCs) in this study.
There were several notable findings in some individual
EGFR pathway mutations in this study. Inactivating mutation
of PTEN has been reported to be rare in NSCLCs, although
loss of PTEN expression has been frequently observed.38,39
Using one of the largest number of resected NSCLCs to date,
we have observed that PTEN mutations were relatively com-
mon, particularly in SCCs, in this Korean series of
NSCLCs.14 Mutations in the LKB1 gene have been reported
to be relatively uncommon (3–5%) in NSCLCs from Asian
patients, although they reportedly occur in 20 to 30% of
NSCLCs of western origin.13,40 In this study, only a single
AC from a male ever smoker harbored an LKB1 mutation.
Because corresponding normal tissues in the same tumors and
DNAs from healthy persons had not been examined in most
of the previous studies, there was no definite discrimination
between somatic and germline origin and no certainty as to
whether they were mutations or polymorphisms.15 There-
fore, the real frequency of LKB1 mutations may be much
lower than previously reported. Although mutations in
ERBB3, ERBB4, NRAS, and AKT1 have been reported to
exist in lung cancer,41– 44 we did not observe these muta-
tions in our population. The overall frequency of TP53
mutations in this study was relatively low (37.6%). How-
ever, when divided by histologic type, the frequency of
TP53 mutations was 58.9% in SCCs and 27.4% in ACs,
which was compatible with previous reports18,45 and the
International Agency for Research on Cancer (IARC)
database (available at: http://www-p53.iarc.fr). Therefore,
the relatively low frequency of TP53 mutations is likely
due to the composition of the study population.
In conclusion, this study showed that mutations in each
part of the EGFR pathway—receptor TKs and downstream
signaling pathways—were associated with different clinico-
pathologic features. Our data suggest that mutations in
PIK3CA/PTEN genes may play an important role in the
pathogenesis of SCCs. These results may contribute to a
better understanding of mutations in EGFR pathway genes in
NSCLCs.
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